Oncogenic over-expression of MED12 is epigenetically fostered in the core-binding factor subgroups of acute myeloid leukemia

被引：0
|
作者：
Choudhury, Samrat Roy
Bhattacharya, Arkajyoti
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4762
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4762
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Is age just a number? Intensive therapy for core-binding factor acute myeloid leukemia in older adults
    George, Benson M.
    Luskin, Marlise R.
    HAEMATOLOGICA, 2025, 110 (03) : 543 - 545
  • [42] Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia
    Rojek, Alexandra E.
    McCormick, Benjamin J.
    Cwykiel, Joanna
    Odetola, Oluwatobi
    Abaza, Yasmin
    Achar, Rohan
    Shallis, Rory M.
    Bradshaw, Danielle
    Standridge, Meaghan
    Kota, Vamsi K.
    Badar, Talha
    Patel, Anand Ashwin
    BLOOD, 2023, 142
  • [43] An ETV6::NTRK3 fusion transcript in a core-binding factor acute myeloid leukemia
    Coster, Lucie
    Huguet, Francoise
    Canali, Alban
    Rieu, Jean-Baptiste
    Mansat-De Mas, Veronique
    EJHAEM, 2023, 4 (03): : 867 - 868
  • [44] Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia
    Bourne, Garrett
    Diebold, Kendall
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    BLOOD, 2023, 142
  • [45] RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
    Kim, TaeHyung
    Moon, Joon Ho
    Ahn, Jae-Sook
    Ahn, Seo-Yeon
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Lee, Je-Jung
    Shin, Myung-Geun
    Choi, Seung Hyun
    Lee, Ja-yeon
    Tyndel, Marc S.
    Lee, Hui Young
    Kim, Kyoung Ha
    Cai, Yu
    Lee, Yoo Jin
    Sohn, Sang Kyun
    Min, Yoo Hong
    Cheong, June-Won
    Kim, Hyeoung-Joon
    Zhang, Zhaolei
    Kim, Dennis Dong Hwan
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [46] Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia
    Bourne, Garrett
    Diebold, Kendall
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    LEUKEMIA RESEARCH, 2024, 139
  • [47] RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
    TaeHyung Kim
    Joon Ho Moon
    Jae-Sook Ahn
    Seo-Yeon Ahn
    Sung-Hoon Jung
    Deok-Hwan Yang
    Je-Jung Lee
    Myung-Geun Shin
    Seung Hyun Choi
    Ja-yeon Lee
    Marc S. Tyndel
    Hui Young Lee
    Kyoung Ha Kim
    Yu Cai
    Yoo Jin Lee
    Sang Kyun Sohn
    Yoo Hong Min
    June-Won Cheong
    Hyeoung-Joon Kim
    Zhaolei Zhang
    Dennis Dong Hwan Kim
    Scientific Reports, 10
  • [48] Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
    Hospital, Marie-Anne
    Prebet, Thomas
    Bertoli, Sarah
    Thomas, Xavier
    Tavernier, Emmanuelle
    Braun, Thorsten
    Pautas, Cecile
    Perrot, Aurore
    Lioure, Bruno
    Rousselot, Philippe
    Tamburini, Jerome
    Cluzeau, Thomas
    Konopacki, Johanna
    Randriamalala, Edouard
    Berthon, Celine
    Gourin, Marie-Pierre
    Recher, Christian
    Cahn, Jean-Yves
    Ifrah, Norbert
    Dombret, Herve
    Boissel, Nicolas
    BLOOD, 2014, 124 (08) : 1312 - 1319
  • [49] Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications
    M. P. Strout
    G. Marcucci
    M. A. Caligiuri
    C. D. Bloomfield
    Annals of Hematology, 1999, 78 : 251 - 264
  • [50] Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications
    Strout, MP
    Marcucci, G
    Caligiuri, MA
    Bloomfield, CD
    ANNALS OF HEMATOLOGY, 1999, 78 (06) : 251 - 264
12345